These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36428172)
1. Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases. de Gaetano M Semin Immunol; 2023 Jan; 65():101699. PubMed ID: 36428172 [TBL] [Abstract][Full Text] [Related]
2. Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies. Millar B; de Gaetano M Front Pharmacol; 2023; 14():1125858. PubMed ID: 36865918 [TBL] [Abstract][Full Text] [Related]
4. Resolution therapy: Harnessing efferocytic macrophages to trigger the resolution of inflammation. Saas P; Vetter M; Maraux M; Bonnefoy F; Perruche S Front Immunol; 2022; 13():1021413. PubMed ID: 36389733 [TBL] [Abstract][Full Text] [Related]
5. Lipoxin Mimetics and the Resolution of Inflammation. Godson C; Guiry P; Brennan E Annu Rev Pharmacol Toxicol; 2023 Jan; 63():429-448. PubMed ID: 36662584 [TBL] [Abstract][Full Text] [Related]
6. Taking insult from injury: lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells. Maderna P; Godson C Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):179-87. PubMed ID: 15978792 [TBL] [Abstract][Full Text] [Related]
7. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. Mitchell S; Thomas G; Harvey K; Cottell D; Reville K; Berlasconi G; Petasis NA; Erwig L; Rees AJ; Savill J; Brady HR; Godson C J Am Soc Nephrol; 2002 Oct; 13(10):2497-507. PubMed ID: 12239238 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation. Galvão I; Melo EM; de Oliveira VLS; Vago JP; Queiroz-Junior C; de Gaetano M; Brennan E; Gahan K; Guiry PJ; Godson C; Teixeira MM Pharmacol Res; 2021 Mar; 165():105445. PubMed ID: 33493655 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199 [TBL] [Abstract][Full Text] [Related]
10. Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A de Gaetano M; Butler E; Gahan K; Zanetti A; Marai M; Chen J; Cacace A; Hams E; Maingot C; McLoughlin A; Brennan E; Leroy X; Loscher CE; Fallon P; Perretti M; Godson C; Guiry PJ Eur J Med Chem; 2019 Jan; 162():80-108. PubMed ID: 30419493 [TBL] [Abstract][Full Text] [Related]
11. Lipoxins: regulators of resolution. Ryan A; Godson C Curr Opin Pharmacol; 2010 Apr; 10(2):166-72. PubMed ID: 20226737 [TBL] [Abstract][Full Text] [Related]
12. Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways. Tylek K; Trojan E; Leśkiewicz M; Regulska M; Bryniarska N; Curzytek K; Lacivita E; Leopoldo M; Basta-Kaim A Cells; 2021 Sep; 10(9):. PubMed ID: 34572022 [TBL] [Abstract][Full Text] [Related]
16. Natural resolution of inflammation. Freire MO; Van Dyke TE Periodontol 2000; 2013 Oct; 63(1):149-64. PubMed ID: 23931059 [TBL] [Abstract][Full Text] [Related]
17. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A de Gaetano M; Tighe C; Gahan K; Zanetti A; Chen J; Newson J; Cacace A; Marai M; Gaffney A; Brennan E; Kantharidis P; Cooper ME; Leroy X; Perretti M; Gilroy D; Godson C; Guiry PJ J Med Chem; 2021 Jul; 64(13):9193-9216. PubMed ID: 34138563 [TBL] [Abstract][Full Text] [Related]
18. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Serhan CN Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):141-62. PubMed ID: 16005201 [TBL] [Abstract][Full Text] [Related]
19. Efferocytosis in health and disease. Doran AC; Yurdagul A; Tabas I Nat Rev Immunol; 2020 Apr; 20(4):254-267. PubMed ID: 31822793 [TBL] [Abstract][Full Text] [Related]
20. Resolution of inflammation: mechanisms and opportunity for drug development. Alessandri AL; Sousa LP; Lucas CD; Rossi AG; Pinho V; Teixeira MM Pharmacol Ther; 2013 Aug; 139(2):189-212. PubMed ID: 23583354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]